GESCO SE Releases 9-Month 2025 Report

GESCO SE has unveiled its 9-month 2025 report, highlighting stable sales and a notable earnings improvement amidst challenging geopolitical conditions. The company, facing reduced expectations for Q4, adjusted its annual forecast.

From January to September, GESCO's incoming orders dipped by 6.4% to €375 million, and sales fell 4.7% to €364.7 million. Yet, EBITDA climbed 6.4% to €28.2 million, and EBIT surged 20.4% to €15.3 million. Group earnings after minority interests grew 55.1%, with earnings per share at €0.80.

The Materials Refinement & Distribution segment struggled, with orders and sales dropping, impacting EBIT and return on sales. Health Care & Lifescience saw slight sales growth and improved EBIT due to cost efficiencies. Industrial Assets & Infrastructure experienced strong order and sales increases post-Eckart acquisition, bolstering EBIT and its book-to-bill ratio.

With recent challenges impacting orders and earnings, the Executive Board narrowed its forecast to €480-500 million in sales and €9-12 million in net income.